DocWire News Editors

DocwireNews

Research has shown that patients with early-stage breast cancer who receive accelerated partial breast irradiation (APBI) via high dose rate (HDR) implant twice daily for five days have outcomes similar to those who undergo whole breast external radiation therapy (XRT) once daily for five to six weeks in terms of breast tumor local recurrence; however, the APBI implant is associated with significant complications. Newer findings observed that APBI using non-invasive intensity modulated radiation therapy (IMRT) or stereotactic body radiation therapy (SBRT) given once daily in five fractions is not inferior to once daily six-week XRT in terms of local recurrence; IMRT/SBRT had better comparative outcomes in terms of acute and late effects, as well as cosmesis. The IMRT/SBRT study defined the clinical target volume (CTV) by the injection of individual fiducial markers on the border of the surgical cavity.In a study presented at the San Antonio Breast Cancer Symposium, researchers sought to confirm the previous IMRT/SBRT findings but with a simpler fiducial system.The researchers evaluated 86 patients who underwent SBRT targeted to a Biozorb-defined CTV with the surgical cavity walls sewn to the Biozorb device. Patients were eligible for inclusion if they were older than 40 years, had a tumor size of 3 cm or smaller, and had negative surgical margins and sentinel node dissections. Patients received SBRT 30 Gy in five fractions.Median follow-up was 12 months (range, 1-24 months). At the time of publication, none of the patients presented local recurrence, and no skin reactions were reported. One case of pain around the Biozorb site was documented, which was resolved following a short course of steroids. Cosmesis was graded as &ldquo;excellent&rdquo; in 100% of cases by the surgeon, radiation oncologist, and nurse.

Jayme Locke, MD, MPH

Joel M. Topf, MD, FACP

The Promise of Xenotransplantation

NKF Spring Clinical Meetings 2025

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

Triple-Negative Breast Cancer

Latest News

IMRT/SBRT Outcomes with Simple Fiducial System

San Antonio Breast Cancer Symposium 2019

Research has shown that patients with early-stage breast cancer who receive accelerated partial breast irradiation (APBI) via high dose rate (HDR) implant twice daily for five ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe